|
|
|
|
|
|
|
12.03.26 - 14:33
|
FUJIFILM Biotechnologies Appoints Christiane Bardroff as Chief Business Officer (Business Wire)
|
|
|
HILLERØD, Denmark--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced the appointment of Christiane Bardroff as Chief Business Officer (CBO), effective June 1, 2026. Bardroff will lead commercial and sales, business insights and intelligence, strategic partnerships and global marketing, reporting directly to President and CEO Lars Petersen.
Bardroff brings more than 18 years of experience and leadership across customer stewardship and biopharmaceutical operations, including process development and small-, mid-, and large-scale manufacturing, quality control, and quality assurance, as well as procurement, automation, and digitalization. Most recently, she was Chief Operating Officer at Rentschler Biopharma SE. Previously, she advanced through roles of increasing responsibility at Teva Biotech and Roche. As a people-first leader, she previously oversaw approximately 1,300 empl...
|
|
|
12.03.26 - 13:01
|
Bavarian Nordic and SII sign agreement for chikungunya vaccine production (PBR)
|
|
|
The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low-
The post Bavarian Nordic and SII sign agreement for chikungunya vaccine production appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
11.03.26 - 13:03
|
Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President, Alzheimer′s Portfolio (Business Wire)
|
|
|
Former Eisai and Eli Lilly Alzheimer's disease leader joins executive team to advance commercialization strategy for Spectris™CAMBRIDGE, Mass.--(BUSINESS WIRE)--#alzheimers--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive therapies for neurodegenerative diseases, today announced the appointment of Thomas Fagan as Executive Vice President, Alzheimer's Portfolio, and a member of the company's Executive Leadership Team.
Mr. Fagan brings more than 25 years of leadership experience across the pharmaceutical, medical device, and diagnostics industries, with deep expertise in Alzheimer's disease spanning diagnostics, therapeutics, and real-world clinical adoption. He has extensive experience building and aligning cross-functional teams, developing clinical-to-commercial pathways, and working with clinicians, health systems, and payers to accelerate adoption of innovative medical technologies.
In his role at Cognito, Mr. Fagan will lead the company's Alzheimer's...
|
|
|
|
|
|
|
11.03.26 - 04:18
|
Takeda Named Chair of Japan-South Korea Parliamentarians′ Union (Nippon)
|
|
|
Tokyo, March 11 (Jiji Press)--Former Japanese interior affairs minister Ryota Takeda was appointed chair of the Japan-South Korea parliamentarians' union, a suprapartisan group of Japanese lawmakers promoting ties between the two countries, on Tuesday. Takeda, a member of the ruling Liberal Democratic Party, succeeded former Prime Minister Yoshihide Suga, an LDP member who has retired from ......
|
|
|
|
|
|
|
|
|
|
|
|
|
06.03.26 - 14:03
|
Third-party payors ("TPPs") in the U.S. that purchased, paid for, and/or reimbursed all or any portion of the price for Actos, ActosPlus MET, ActosPlus MET XR, Duetact, and/or Oseni, for five or more independent prescriptions, between July (PR Newswire)
|
|
|
LOS ANGELES, March 6, 2026 /PRNewswire/ -- What is the lawsuit about? A National Third-Party Payor ("TPP") Class has been certified in a class action lawsuit against Defendant Takeda Pharmaceuticals USA, Inc. and its parent company Defendant Takeda Pharmaceutical Company Limited (jointly,......
|
|
|
05.03.26 - 09:06
|
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
